Format

Send to

Choose Destination
See comment in PubMed Commons below
J Mol Biol. 2014 Jun 12;426(12):2283-99. doi: 10.1016/j.jmb.2014.03.011. Epub 2014 Mar 27.

A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.

Author information

  • 1Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
  • 2Department of Biology, Syracuse University, Syracuse, NY 13210, USA.
  • 3Department of Genome Sciences, University of Washington Seattle, Seattle, WA 98105, USA.
  • 4Department of Genome Sciences, University of Washington Seattle, Seattle, WA 98105, USA; Department of Pediatrics, University of Washington Seattle, Seattle, WA 98195, USA.
  • 5Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA. Electronic address: cosgrovm@upstate.edu.

Abstract

The mixed lineage leukemia-1 (MLL1) enzyme is a histone H3 lysine 4 (H3K4) monomethyltransferase and has served as a paradigm for understanding the mechanism of action of the human SET1 family of enzymes that include MLL1-MLL4 and SETd1a,b. Dimethylation of H3K4 requires a sub-complex including WRAD (WDR5, RbBP5, Ash2L, and DPY-30), which binds to each SET1 family member forming a minimal core complex that is required for multiple lysine methylation. We recently demonstrated that WRAD is a novel histone methyltransferase that preferentially catalyzes H3K4 dimethylation in a manner that is dependent on an unknown non-active-site surface from the MLL1 SET domain. Recent genome sequencing studies have identified a number of human disease-associated missense mutations that localize to the SET domains of several MLL family members. In this investigation, we mapped many of these mutations onto the three-dimensional structure of the SET domain and noticed that a subset of MLL2 (KMT2D, ALR, MLL4)-associated Kabuki syndrome missense mutations map to a common solvent-exposed surface that is not expected to alter enzymatic activity. We introduced these mutations into the MLL1 SET domain and observed that all are defective for H3K4 dimethylation by the MLL1 core complex, which is associated with a loss of the ability of MLL1 to interact with WRAD or with the RbBP5/Ash2L heterodimer. Our results suggest that amino acids from this surface, which we term the Kabuki interaction surface or KIS, are required for formation of a second active site within SET1 family core complexes.

KEYWORDS:

Kabuki syndrome; RbBP5/Ash2L; SET domain; histone methylation; mixed lineage leukemia

PMID:
24680668
PMCID:
PMC4066448
DOI:
10.1016/j.jmb.2014.03.011
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center